ImageneBio, Inc.
IMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001835579
In the last 90 days, ImageneBio, Inc. insiders filed 0 open-market purchases and 1 sale; 35 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in ImageneBio, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 42
- −3 vs. Q2 2022
- Shares held
- 26.2M
- −539.6K (−2.0%) vs. Q2 2022
- Total value
- $93.2M
- −$25.5M (−21.5%) vs. Q2 2022
- New holders
- 5
- 18 more added
- Sold out
- 8
- 7 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $36.8M |
| Q1 2026 | 39 | $26.8M |
| Q4 2025 | 41 | $32.9M |
| Q3 2025 | 33 | $38.3M |
| Q2 2025 | 41 | $42.6M |
| Q1 2025 | 46 | $41.9M |
| Q4 2024 | 53 | $52.0M |
| Q3 2024 | 57 | $49.1M |
| Q2 2024 | 70 | $47.9M |
| Q1 2024 | 57 | $42.7M |
| Q4 2023 | 54 | $63.8M |
| Q3 2023 | 58 | $141.6M |
| Q2 2023 | 52 | $204.7M |
| Q1 2023 | 39 | $86.2M |
| Q4 2022 | 34 | $69.9M |
| Q3 2022 | 42 | $93.2M |
| Q2 2022 | 46 | $118.7M |
| Q1 2022 | 48 | $167.8M |
| Q4 2021 | 49 | $343.6M |
| Q3 2021 | 39 | $271.8M |
| Q2 2021 | 42 | $293.2M |
| Q1 2021 | 27 | $538.5M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding ImageneBio, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,018,178 | $17.8M | 1.97% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,933,941 | $10.4M | 0.21% | 00.0% | Unchanged |
| FMR LLC | 2,526,203 | $8.97M | 0.00% | −1,869,516−42.5% | Reduced |
| BVF Inc | 2,503,071 | $8.89M | 0.37% | 00.0% | Unchanged |
| Omega Fund Management, LLC | 2,249,123 | $7.98M | 2.92% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,158,479 | $7.66M | 0.01% | +32,078+1.5% | Added |
| Artal Group S.A. | 1,549,513 | $5.50M | 0.29% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 1,343,496 | $4.77M | 0.02% | +654,800+95.1% | Added |
| Verition Fund Management LLC | 1,299,255 | $4.61M | 0.06% | +277,365+27.1% | Added |
| CHI Advisors LLC | 1,214,304 | $4.31M | 1.16% | +123,367+11.3% | Added |
| Vanguard Group Inc | 979,003 | $3.48M | 0.00% | +304,898+45.2% | Added |
| Laurion Capital Management LP | 529,000 | $1.88M | 0.05% | 00.0% | Unchanged |
| BlackRock Inc. | 502,152 | $1.78M | 0.00% | +214,404+74.5% | Added |
| Geode Capital Management, LLC | 236,948 | $841.0K | 0.00% | +134,274+130.8% | Added |
| HealthCor Management, L.P. | 220,082 | $781.0K | 0.10% | 00.0% | Unchanged |
| Barclays PLC | 201,227 | $714.0K | 0.00% | +132+0.1% | Added |
| Oasis Management Co Ltd. | 140,000 | $497.0K | 0.09% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 122,517 | $435.0K | 0.12% | +122,517 | New |
| Ergoteles LLC | 100,640 | $357.0K | 0.01% | −15,401−13.3% | Reduced |
| Bridgeway Capital Management, LLC | 91,800 | $326.0K | 0.01% | +78,800+606.2% | Added |
| Ensign Peak Advisors, Inc | 90,310 | $321.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 51,515 | $183.0K | 0.00% | −23,592−31.4% | Reduced |
| State Street Corp | 31,553 | $112.0K | 0.00% | −12,703−28.7% | Reduced |
| Cornercap Investment Counsel Inc | 29,465 | $105.0K | 0.02% | +12,829+77.1% | Added |
| Northern Trust Corp | 27,234 | $97.0K | 0.00% | +11,800+76.5% | Added |
| Dimensional Fund Advisors LP | 25,145 | $90.0K | 0.00% | +15,013+148.2% | Added |
| Qube Research & Technologies Ltd | 19,201 | $68.0K | 0.00% | −5,131−21.1% | Reduced |
| Acadian Asset Management LLC | 13,301 | $45.0K | 0.00% | +3,103+30.4% | Added |
| Goldman Sachs Group Inc | 12,428 | $44.0K | 0.00% | −11,142−47.3% | Reduced |
| Charles Schwab Investment Management Inc | 12,066 | $43.0K | 0.00% | +12,066 | New |
| Tower Research Capital LLC (TRC) | 3,842 | $13.0K | 0.00% | +679+21.5% | Added |
| Baystate Wealth Management LLC | 2,999 | $11.0K | 0.00% | 00.0% | Unchanged |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 2,472 | $9.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 2,445 | $9.00K | 0.00% | +1,071+77.9% | Added |
| BNP Paribas Arbitrage, SA | 976 | $3.46K | 0.00% | +976 | New |
| Citigroup Inc | 679 | $2.00K | 0.00% | −257−27.5% | Reduced |
| Bank of America Corp | 617 | $2.00K | 0.00% | +309+100.3% | Added |
| MUFG Americas Holdings Corp | 450 | $2.00K | 0.00% | +450 | New |
| Royal Bank of Canada | 231 | $1.00K | 0.00% | +36+18.5% | Added |
| Wells Fargo & Company | 266 | $1.00K | 0.00% | +103+63.2% | Added |
| China Universal Asset Management Co., Ltd. | 340 | $1.00K | 0.00% | +340 | New |
| Daiwa Securities Group Inc. | 105 | $0 | 0.00% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 0 | $0 | 0.00% | −290,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −235,818−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −40,915−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −20,720−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −15,544−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −201−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Private Capital Group, LLC | – | – | – | – | Not filed |